W K Yung

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi Se-methylselenocysteine inhibits phosphatidylinositol 3-kinase activity of mouse mammary epithelial tumor cells in vitro
    Emmanual Unni
    Medicine Endocrinology, Baylor College of Medicine, Houston, Texas, USA
    Breast Cancer Res 7:R699-707. 2005
  2. ncbi NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas
    Ta Jen Liu
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Unit 431, 1515 Holcombe Boulevard, Houston, TX 77030
    Mol Cancer Ther 8:2204-10. 2009
  3. ncbi Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study
    W K Alfred Yung
    Department of Neuro Oncology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Neuro Oncol 12:1061-70. 2010
  4. ncbi Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma
    Dimpy Koul
    Brain Tumor Center, Department of Neuro-Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 100, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Mol Cancer Ther 4:1681-8. 2005
  5. ncbi Targeting in gene therapy for gliomas
    J Fueyo
    Department of Neuro Oncology, University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Arch Neurol 56:445-8. 1999
  6. ncbi Co-expression of E2F-2 enhances the p53 anti-cancer effect in human glioma cells
    P G Mitlianga
    Department of Neuro-Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Int J Oncol 18:343-7. 2001
  7. ncbi Identification of a novel gene product, RIG, that is down-regulated in human glioblastoma
    A H Ligon
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Oncogene 14:1075-81. 1997
  8. ncbi Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group
    W K Yung
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 17:2762-71. 1999
  9. ncbi Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme
    Morris D Groves
    Department of Neuro-Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:1383-8. 2002
  10. ncbi Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan
    Candelaria Gomez-Manzano
    Department of Neuro-Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 12:556-62. 2006

Research Grants

  1. TRIPLE ANTI ANGIOGENIC THERAPY FOR BRIAN TUMORS
    W K Yung; Fiscal Year: 2002
  2. Analysis of a 10Q Tumor Suppressor Gene
    W K Yung; Fiscal Year: 2007
  3. Triple Anti-Angiogenic Therapy for Brain Tumors
    W K Yung; Fiscal Year: 2007
  4. Deciphering synergistic combinatorial targets in glioma
    W K Yung; Fiscal Year: 2007
  5. Deciphering synergistic combinatorial targets in glioma
    W K Yung; Fiscal Year: 2009
  6. 10Q TUMOR SUPPRESSOR GENE
    W K Yung; Fiscal Year: 2002
  7. Deciphering synergistic combinatorial targets in glioma
    W K Alfred Yung; Fiscal Year: 2010

Collaborators

Detail Information

Publications95

  1. ncbi Se-methylselenocysteine inhibits phosphatidylinositol 3-kinase activity of mouse mammary epithelial tumor cells in vitro
    Emmanual Unni
    Medicine Endocrinology, Baylor College of Medicine, Houston, Texas, USA
    Breast Cancer Res 7:R699-707. 2005
    ..The present study was designed to examine the involvement of the phosphatidylinositol 3-kinase (PI3-K) pathway in TM6 tumor model in vitro after treatment with MSC...
  2. ncbi NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas
    Ta Jen Liu
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Unit 431, 1515 Holcombe Boulevard, Houston, TX 77030
    Mol Cancer Ther 8:2204-10. 2009
    ..These results warrant further development of NVP-BEZ235 for clinical trials for human gliomas or other advanced cancers with altered PI3K/Akt/mTOR signaling...
  3. ncbi Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study
    W K Alfred Yung
    Department of Neuro Oncology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Neuro Oncol 12:1061-70. 2010
    ..EGFR amplification was not associated with erlotinib activity. Given the large CIs and nonrandomized nature of the study, results should be interpreted cautiously...
  4. ncbi Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma
    Dimpy Koul
    Brain Tumor Center, Department of Neuro-Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 100, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Mol Cancer Ther 4:1681-8. 2005
    ..Thus, blocking the ILK/Akt pathway is a potential strategy for molecular targeted therapy for gliomas...
  5. ncbi Targeting in gene therapy for gliomas
    J Fueyo
    Department of Neuro Oncology, University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Arch Neurol 56:445-8. 1999
    ..In summary, in this review, we highlight the translational advances in molecular medicine that broaden our battery of therapies for patients with brain tumors...
  6. ncbi Co-expression of E2F-2 enhances the p53 anti-cancer effect in human glioma cells
    P G Mitlianga
    Department of Neuro-Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Int J Oncol 18:343-7. 2001
    ..These results show that co-expression of E2F-2 and p53 enhances the anti-cancer effect of p53 in gliomas...
  7. ncbi Identification of a novel gene product, RIG, that is down-regulated in human glioblastoma
    A H Ligon
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Oncogene 14:1075-81. 1997
    ..The differential expression pattern, tissue distribution and chromosomal location of RIG suggests it serves as a molecular marker for or may play a role in the malignant progression of GBMs...
  8. ncbi Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group
    W K Yung
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 17:2762-71. 1999
    ..To determine the antitumor efficacy and safety profile of temozolomide in patients with malignant astrocytoma at first relapse...
  9. ncbi Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme
    Morris D Groves
    Department of Neuro-Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:1383-8. 2002
    ..This drug combination met phase II study criteria; further study in recurrent patients with GBM might be warranted. Further study of therapy-induced joint pain is necessary...
  10. ncbi Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan
    Candelaria Gomez-Manzano
    Department of Neuro-Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 12:556-62. 2006
    ....
  11. ncbi Functional and molecular analyses of 10q deletions in human gliomas
    P A Steck
    Department of Neuro Oncology, The Brain Tumor Center, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Genes Chromosomes Cancer 24:135-43. 1999
    ..These results support a model of molecular progression in gliomas in which the frequent deletion of 10q25-26 is an early event and is followed by the deletion of the MMAC/PTEN during the progression to high-grade GBMs...
  12. ncbi Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study
    Kurt A Jaeckle
    University of Texas M D Anderson Cancer Center, Houston, USA
    J Clin Oncol 21:2305-11. 2003
    ..This phase II trial evaluated efficacy and toxicity of combination temozolomide and cRA treatment in recurrent MG...
  13. ncbi Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study
    Monica E Loghin
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:7133-8. 2007
    ..The study was also intended to assess whether temozolomide affects the conversion of irinotecan to SN-38...
  14. ncbi Differential activation of the Fas/CD95 pathway by Ad-p53 in human gliomas
    Julie A Cerrato
    The Brain Tumor Center, Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Oncol 24:409-17. 2004
    ..Further elucidation of the nature of this resistance could ultimately augment the efficacy of Ad-p53 gene therapy...
  15. ncbi Mechanisms underlying PTEN regulation of vascular endothelial growth factor and angiogenesis
    Candelaria Gomez-Manzano
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Ann Neurol 53:109-17. 2003
    ....
  16. ncbi MMAC/PTEN tumor suppressor gene regulates vascular endothelial growth factor-mediated angiogenesis in prostate cancer
    Dimpy Koul
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Int J Oncol 21:469-75. 2002
    ..Concomitant with lessened VEGF expression was the reduction of VEGF promoter activity in PTEN-expressing cells. Our findings suggest that PTEN modulates angiogenesis by regulating VEGF expression...
  17. ncbi Comparative effect of oncolytic adenoviruses with E1A-55 kDa or E1B-55 kDa deletions in malignant gliomas
    Hong Jiang
    Brain Tumor Center, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Neoplasia 7:48-56. 2005
    ....
  18. ncbi Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma
    Christopher E Pelloski
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 12:3935-41. 2006
    ..This study was conducted to determine whether any of these markers are associated with survival time and response to radiation in glioblastoma...
  19. ncbi Genetically modified adenoviruses against gliomas: from bench to bedside
    Candelaria Gomez-Manzano
    Department of Neuro-Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
    Neurology 63:418-26. 2004
    ....
  20. ncbi Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades
    Yiling Lu
    Department of Molecular Therapeutics, Division of Cancer Medicine, M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Biol Chem 278:40057-66. 2003
    ..Coexpression of PTEN with activated Src reduces the stability of PTEN. Taken together, the data indicate that activated Src inhibits PTEN function leading to alterations in signaling through the PI3K/AKT pathway...
  21. ncbi Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance
    Marta M Alonso
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Natl Cancer Inst 97:1589-600. 2005
    ..Several tumor suppressor pathways have been identified as modulators of telomerase function. We examined the functional role of the retinoblastoma-E2F1 pathway in regulating telomerase activity in malignant gliomas...
  22. ncbi CI-980 for the treatment of recurrent or progressive malignant gliomas: national central nervous system consortium phase I-II evaluation of CI-980
    Lara J Kunschner
    Department of Neuro-Oncology, M.D. Anderson Cancer Center, University of Texas, Box 431, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Invest 20:948-54. 2002
    ..Three episodes of neurotoxicity manifested by a moderate cerebellar dysfunction were seen. CONCLUSIONS: These results fail to demonstrate the significant activity of CI-980 against recurrent glioma...
  23. ncbi Cell cycle-dependent nuclear export of phosphatase and tensin homologue tumor suppressor is regulated by the phosphoinositide-3-kinase signaling cascade
    Juinn Lin Liu
    Brain Tumor Center and Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 67:11054-63. 2007
    ..This scenario exemplifies a reciprocal regulation between PI3K and PTEN that defines a novel negative-feedback loop in cell cycle progression...
  24. ncbi The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival
    Yi-Hong Zhou
    Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:3369-75. 2003
    ....
  25. ncbi Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity
    Dimpy Koul
    Department of Neuro Oncology, Box 100, The Brain Tumor Center, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas, TX 77030, USA
    Oncogene 21:2357-64. 2002
    ..Thus, Y240A and Y315A are involved in the ability of MMAC/PTEN to dephosphorylate PtdIns and regulate tumor cell growth in vitro and in vivo...
  26. ncbi Downmodulation of E1A protein expression as a novel strategy to design cancer-selective adenoviruses
    Hong Jiang
    Department of Neuro-Oncology, Brain Tumor Center, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Neoplasia 7:723-9. 2005
    ..We conclude that the level of E1A protein is a critical determinant of oncolytic phenotype and we propose a completely novel strategy for the design and construction of conditionally replicative adenoviruses...
  27. ncbi Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM
    Yong Wan Kim
    Brain Tumor Center, Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Neuro Oncol 13:367-75. 2011
    ..Our findings suggest that inhibition of these pathways might increase tumor sensitivity to PX-866 and therefore represent a potential clinical therapeutic strategy...
  28. ncbi Advances in translational research in neuro-oncology
    Juan Fueyo
    Department of Neuro Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Arch Neurol 68:303-8. 2011
    ....
  29. ncbi Regulation of MMP-9 (type IV collagenase) production and invasiveness in gliomas by the extracellular signal-regulated kinase and jun amino-terminal kinase signaling cascades
    S S Lakka
    Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, USA
    Clin Exp Metastasis 18:245-52. 2000
    ....
  30. ncbi Cognitive function as a predictor of survival in patients with recurrent malignant glioma
    C A Meyers
    Departments of Neuro Oncology and Biomathematics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 18:646-50. 2000
    ..To determine the contribution of cognitive function in predicting the survival of patients with recurrent malignant brain tumors...
  31. ncbi TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors
    S E Kaba
    Department of Neuro Oncology and Biomathematics, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    J Clin Oncol 15:1063-70. 1997
    ..To evaluate a combination of thioguanine, procarbazine, dibromodulcitol, CCNU (CCNU), fluorouracil, and hydroxyurea (TPDC-FuHu), designed to improve the efficacy of CCNU, in the treatment of recurrent metastatic brain tumors...
  32. ncbi The excitatory amino acid transporter-2 induces apoptosis and decreases glioma growth in vitro and in vivo
    John F de Groot
    The Brain Tumor Center, Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 65:1934-40. 2005
    ..Further studies will improve our knowledge of the role of glutamate in glioma growth and may provide useful prognostic information and alternative therapeutic targets for the treatment of glioma...
  33. ncbi Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo
    Ta Jen Liu
    Brain Tumor Center, Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer Ther 6:1357-67. 2007
    ..Collectively, these data show that blocking the signaling pathways of FAK and IGF-IR with TAE226 has the potential to be an efficacious treatment for human gliomas...
  34. ncbi A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma
    Mark R Gilbert
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Unit 431, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Neuro Oncol 12:1167-72. 2010
    ..Multiple cytostatic agents can be safely combined with dose-dense temozolomide. The factorial-based phase II portion of this study is currently ongoing...
  35. ncbi PTEN down regulates AP-1 and targets c-fos in human glioma cells via PI3-kinase/Akt pathway
    Dimpy Koul
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cell Biochem 300:77-87. 2007
    ....
  36. ncbi Mitogen-activated protein kinase kinase-4 promotes cell survival by decreasing PTEN expression through an NF kappa B-dependent pathway
    Dianren Xia
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA
    J Biol Chem 282:3507-19. 2007
    ..Thus, MKK4 promotes cell survival by activating phosphatidylinositol 3-kinase through an NFkappaB/PTEN-dependent pathway...
  37. ncbi Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-beta for supratentorial glioblastoma: results of RTOG 9710
    Howard Colman
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 66:818-24. 2006
    ..The aim of this study was to determine whether recombinant human interferon beta-1a (rhIFN-beta), when given after radiation therapy, improves survival in glioblastoma...
  38. ncbi A novel CRM1-dependent nuclear export signal in adenoviral E1A protein regulated by phosphorylation
    Hong Jiang
    Department of Neuro Oncology, Unit 1002, Brain Tumor Center, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    FASEB J 20:2603-5. 2006
    ..Collectively, our data demonstrate the existence of a NES in E1A that is modulated by the phosphorylation of the S89 residue and the NES plays a role for an efficient viral replication in the host cells...
  39. ncbi PTEN enhances TNF-induced apoptosis through modulation of nuclear factor-kappaB signaling pathway in human glioma cells
    Dimpy Koul
    Brain Tumor Center, Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Biochem Biophys Res Commun 350:463-71. 2006
    ....
  40. ncbi Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation
    Victor A Levin
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Neurooncol 78:295-302. 2006
    ..Because raised matrix metalloprotease (MMP) levels are associated with glioma invasion and angiogenesis, we tested the efficacy of marimastat (MT) an orally active drug that can reduce MMP levels, in patients with gliomas...
  41. ncbi A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme
    Morris D Groves
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, 1400 Holcombe, 431, Houston, TX, 77030, USA
    J Neurooncol 81:271-7. 2007
    ..Laboratory and clinical data suggest that the anti-angiogenic agent, thalidomide, if combined with cytotoxic agents, may be effective against recurrent glioblastoma multiforme (GBM)...
  42. ncbi Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results
    Frederick F Lang
    Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    J Clin Oncol 21:2508-18. 2003
    ..Advances in brain tumor biology indicate that transfer of p53 is an alternative therapy for human gliomas. Consequently, we undertook a phase I clinical trial of p53 gene therapy using an adenovirus vector (Ad-p53, INGN 201)...
  43. ncbi Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma
    Dimpy Koul
    Brain Tumor Center, Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Unit 1002, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 5:637-44. 2006
    ..This decrease in cell growth stemmed from the induction of apoptosis. Collectively, these results provide a strong rationale for the pharmacologic targeting of Akt for the treatment of gliomas...
  44. ncbi Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization
    Charles Conrad
    Department of Neuro Oncology, The Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer Gene Ther 12:284-94. 2005
    ..These findings demonstrate that Delta24-hyCD with concomitant systemic 5-FC is a significant improvement over the earlier Delta24 oncolytic tumor-selective strategy for therapy of experimental gliomas...
  45. ncbi A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies
    Morris D Groves
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, 1400 Holcombe Blvd, Houston, TX 77030, USA
    Neuro Oncol 10:208-15. 2008
    ..IVent topotecan is well tolerated, but provides no added benefit over other IVent therapies. Because of its modest side effect profile, combining IVent topotecan with other IVent or systemic interventions should be considered...
  46. ncbi Molecular classification of human diffuse gliomas by multidimensional scaling analysis of gene expression profiles parallels morphology-based classification, correlates with survival, and reveals clinically-relevant novel glioma subsets
    Gregory N Fuller
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Brain Pathol 12:108-16. 2002
    ....
  47. ncbi Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma
    Morris D Groves
    Departments of Neuro Oncology, The Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Neurooncol 94:229-34. 2009
    ..We chose to measure these molecules in the cerebrospinal fluid (CSF) of melanoma, breast, and lung cancer patients being evaluated for neoplastic meningitis (NM)...
  48. ncbi Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas
    Victor A Levin
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 9:981-90. 2003
    ....
  49. ncbi Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway
    Juan Fueyo
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Natl Cancer Inst 95:652-60. 2003
    ..Delta-24-RGD has an RGD-4C peptide motif inserted into the adenoviral fiber, which allows the adenovirus to anchor directly to integrins...
  50. ncbi VEGF Trap induces antiglioma effect at different stages of disease
    Candelaria Gomez-Manzano
    Department of Neuro Oncology, Unit 1002, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Neuro Oncol 10:940-5. 2008
    ..Finally, our results indicate that the clinical success of VEGF Trap may depend on a prolonged treatment in combined therapy aiming to simultaneously inhibit angiogenesis and tumor invasion...
  51. ncbi Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter
    Marta M Alonso
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 67:11499-504. 2007
    ..Collectively, our data provide a strong mechanistic rationale for the combination of oncolytic adenoviruses and temozolomide, and should propel the clinical testing of this therapy approach in patients with malignant gliomas...
  52. ncbi Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and survival
    Vinay K Puduvalli
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Oncology 65:259-66. 2003
    ..In this multicenter retrospective study, we analyzed the clinical characteristics of patients with AO to identify prognostic factors that influence time to progression (TTP) and survival...
  53. ncbi Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status
    Morris D Groves
    Department of Neuro Oncology, Unit 431, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Neurooncol 80:83-90. 2006
    ....
  54. ncbi A novel E1A-E1B mutant adenovirus induces glioma regression in vivo
    Candelaria Gomez-Manzano
    Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncogene 23:1821-8. 2004
    ..The CB1 oncolytic adenovirus induces a potent antiglioma effect and could ultimately demonstrate clinical relevance and therapeutic utility...
  55. ncbi Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme
    Vinay K Puduvalli
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Neuro Oncol 10:216-22. 2008
    ..The results also provide support for similar strategies using combination therapies with newer targeted antiangiogenic agents to generate effective therapies against malignant gliomas...
  56. ncbi Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study
    Vinay K Puduvalli
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 431, Houston TX 77030, USA
    J Clin Oncol 22:4282-9. 2004
    ..Fenretinide induces apoptosis in malignant gliomas in vitro. This two-stage phase II trial was conducted to determine the efficacy of fenretinide in adults with recurrent malignant gliomas...
  57. ncbi Knockdown of GluR1 expression by RNA interference inhibits glioma proliferation
    John F de Groot
    Brain Tumor Center, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Neurooncol 88:121-33. 2008
    ..These results suggest that AMPA receptors are abundantly expressed in high-grade gliomas and gene silencing of the GluR1 AMPA receptor subunit results in abrogation of AMPA-mediated signaling and tumor growth...
  58. ncbi Tumor suppressor MMAC/PTEN inhibits cytokine-induced NFkappaB activation without interfering with the IkappaB degradation pathway
    D Koul
    Department of Neuro-Oncology and the Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    J Biol Chem 276:11402-8. 2001
    ..Taken together, our observations suggest that PI 3-kinase regulates NFkappaB activation through a novel phosphorylation-dependent mechanism...
  59. ncbi Reduced expression of mismatch repair genes measured by multiplex reverse transcription-polymerase chain reaction in human gliomas
    Q Wei
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Cancer Res 57:1673-7. 1997
    ..These data suggest that reduced expression of MMR genes is frequent in human gliomas and that aberrant expression of more than one MMR gene may be associated with increased risk of second primary malignancies in glioma patients...
  60. ncbi A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
    W K Yung
    Department of Neuro Oncology, UTMD Anderson Cancer Center, Box 100, 1515 Holcombe Boulevard, Houston, Texas, 77030, USA
    Br J Cancer 83:588-93. 2000
    ..44% for PCB patients (P = 0.019). Freedom from disease progression was associated with maintenance of HRQL, regardless of treatment received. TMZ had an acceptable safety profile; most adverse events were mild or moderate in severity...
  61. ncbi A reliability test of standard-based quantitative PCR: exogenous vs endogenous standards
    L D Ke
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Mol Cell Probes 14:127-35. 2000
    ..In contrast, exogenous standard-based quantitative PCR was shown to be an accurate and reliable method for the quantitation of gene expression...
  62. ncbi VEGF(121), VEGF(165) overexpression enhances tumorigenicity in U251 MG but not in NG-1 glioma cells
    Li Dao Ke
    Department of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 62:1854-61. 2002
    ..These data suggested that a switch from a phenotype of low tumorigenicity to one of high tumorigenicity is possible when VEGF overexpression occurs, although other factors may also be required...
  63. ncbi Sustained angiopoietin-2 expression disrupts vessel formation and inhibits glioma growth
    Ok Hee Lee
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Neoplasia 8:419-28. 2006
    ..We therefore conclude that deregulated Ang2 expression during gliomagenesis hindered successful angiogenesis and that therapies that sustain Ang2 expression might be effective against malignant gliomas...
  64. ncbi Polymorphisms of DNA repair genes and risk of glioma
    Li E Wang
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 64:5560-3. 2004
    ..13-2.93). These results suggest that the T allele may be a risk allele, and this XRCC7 polymorphism may be a marker for the susceptibility to glioma. Larger studies are needed to confirm our findings and unravel the underlying mechanisms...
  65. ncbi Nuclear PTEN-mediated growth suppression is independent of Akt down-regulation
    Juinn Lin Liu
    Brain Tumor Center, Department of Neuro Oncology, UT M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 431, Houston, Texas 77030, USA
    Mol Cell Biol 25:6211-24. 2005
    ..Our collective results provide the first direct evidence that PTEN can contribute to G1 growth arrest through an Akt-independent signaling pathway...
  66. ncbi Activation of polyamine catabolism by N1,N11-diethylnorspermine leads to cell death in glioblastoma
    Rongcai Jiang
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Oncol 31:431-40. 2007
    ..Taken together, our studies indicate that DENSPM kills GBM cells through induction of SSAT coupled with H2O2 production, which is a potential target for GBM therapy...
  67. ncbi Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy
    Bouthaina S Dabaja
    Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer 98:1021-8. 2003
    ..CONCLUSIONS: Hyperfractionated WBRT with concurrent BUdR after chemotherapy was found to result in modest disease control but has unacceptable neurotoxicity...
  68. ncbi E2F1 and telomerase: alliance in the dark side
    Marta M Alonso
    Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cell Cycle 5:930-5. 2006
    ..We also consider the clinical implications of this association in terms of prognostic significance and opportunities for the development of new and more rational therapeutic strategies...
  69. ncbi Introduction of mutant p53 into a wild-type p53-expressing glioma cell line confers sensitivity to Ad-p53-induced apoptosis
    J A Cerrato
    Department of Neuro-Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Neuro Oncol 3:113-22. 2001
    ..These results underscore the importance of glioma p53 genotype for predicting tumor response to p53-based gene therapy...
  70. ncbi Transfer of E2F-1 to human glioma cells results in transcriptional up-regulation of Bcl-2
    C Gomez-Manzano
    Department of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Cancer Res 61:6693-7. 2001
    ..Our results demonstrate that E2F-1 modulates the expression of the antiapoptotic molecule Bcl-2 and suggest that up-regulation of Bcl-2 may favor the oncogenic role of E2F-1 and other members of the E2F family of transcription factors...
  71. ncbi Promoter analysis of tumor suppressor gene PTEN: identification of minimum promoter region
    Xiaoyang Sheng
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Biochem Biophys Res Commun 292:422-6. 2002
    ..Interestingly, a p53 binding sequence is located within the 599 bp fragment (-1344/-745), although p53 expression had a minimal effect on PTEN, demonstrating its insignificant role in PTEN gene expression...
  72. ncbi Aggregation of cancer in first-degree relatives of patients with glioma
    Michael E Scheurer
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 1439, USA
    Cancer Epidemiol Biomarkers Prev 16:2491-5. 2007
    ..Previous studies have been inconclusive in estimating the risk of different cancer sites among close relatives of glioma patients; however, malignant melanoma has consistently been described...
  73. ncbi c-Jun downregulation by HDAC3-dependent transcriptional repression promotes osmotic stress-induced cell apoptosis
    Yan Xia
    Brain Tumor Center and Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cell 25:219-32. 2007
    ....
  74. ncbi Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma
    Christopher E Pelloski
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 25:2288-94. 2007
    ..We sought to evaluate the clinical significance of GBM subtypes as defined by EGFRvIII status...
  75. ncbi AMPK/TSC2/mTOR-signaling intermediates are not necessary for LKB1-mediated nuclear retention of PTEN tumor suppressor
    Juinn Lin Liu
    Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Neuro Oncol 13:184-94. 2011
    ....
  76. ncbi Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers
    P A Steck
    Department of Neuro Oncology, University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Nat Genet 15:356-62. 1997
    ..Our results identify a strong candidate tumour suppressor gene at chromosome 10q23.3, whose loss of function appears to be associated with the oncogenesis of multiple human cancers...
  77. ncbi Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis
    T Sano
    Department of Neuro Oncology, The Brain Tumor Center, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Cancer Res 59:1820-4. 1999
    ..The combination of these results suggest that, in addition to molecular alterations affecting the gene, altered expression of MMAC/PTEN may play a significant role in the progression of GBM and patient outcome...
  78. ncbi Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer
    M L Wang
    Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Am J Clin Oncol 24:421-4. 2001
    ....
  79. ncbi Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies
    Frederick F Lang
    Department of Neurosurgery, The Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, TX 77005-4009, USA
    Neuro Oncol 4:268-77. 2002
    ..Specifically, the authors recommend brain-applicable phase I and II clinical trial strategies that take advantage of the targeted nature of new agents to maximize information about their efficacy, toxicity, and molecular effects...
  80. ncbi Transgenic E2F1 expression in the mouse brain induces a human-like bimodal pattern of tumors
    Melissa V Olson
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 67:4005-9. 2007
    ..Thus, this study offers the first evidence for a global role of E2F1 in the formation and maintenance of multilineage brain tumors, irrefutably establishing E2F1 as an oncogene in the brain...
  81. ncbi Exploratory analysis of the copy number alterations in glioblastoma multiforme
    Pablo Freire
    Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    PLoS ONE 3:e4076. 2008
    ..The wealth of existing mechanistic information about cancer cell biology provides a natural reference for the exploratory exercise...
  82. ncbi Bevacizumab--news from the fast lane?
    Michael Weller
    Neuro Oncol 10:647. 2008
  83. ncbi Comprehensive genomic characterization defines human glioblastoma genes and core pathways
    Roger McLendon
    Nature 455:1061-8. 2008
    ..Together, these findings establish the feasibility and power of TCGA, demonstrating that it can rapidly expand knowledge of the molecular basis of cancer...
  84. ncbi A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study
    H Ian Robins
    Department of Medicine, University of Wisconsin, Madison, WI 53792, USA
    Neuro Oncol 4:109-14. 2002
    ..The significant myeloprotection afforded by thymidine may have particular relevance to polychemotherapeutic regimens...
  85. ncbi Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08
    Patrick Y Wen
    Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts, USA
    Clin Cancer Res 12:4899-907. 2006
    ..Phase II: To determine the therapeutic efficacy of imatinib...
  86. ncbi Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study
    Michael D Prados
    Department of Neurological Surgery, University of California at San Francisco, San Francisco, CA 94143, USA
    Neuro Oncol 6:33-7. 2004
    ..We conclude that BCNU plus temozolomide when used in these doses and schedule has only modest activity, with significant toxicity, and appears to be no more effective than single-agent temozolomide...
  87. ncbi PAX6 suppresses the invasiveness of glioblastoma cells and the expression of the matrix metalloproteinase-2 gene
    Debra A Mayes
    Department of Neurobiology and Developmental Sciences, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
    Cancer Res 66:9809-17. 2006
    ..Overall data delineated a mechanism for the suppressive function of PAX6 in GBM: suppression of cell invasion by repressing the expression of proinvasive genes such as MMP2...
  88. ncbi Modeling prognosis for patients with malignant astrocytic gliomas: quantifying the expression of multiple genetic markers and clinical variables
    Yi Hong Zhou
    Department of Neurobiology and Developmental Sciences, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Neuro Oncol 7:485-94. 2005
    ..This finding suggests that the expression of IGFBP2 is associated with pathways activated specifically in GBMs that result in enhancing invasiveness and angiogenesis...
  89. ncbi Current therapies for glioblastoma
    W K Alfred Yung
    Department of Neuro-Oncology, University of Texas M. D. Anderson Cancer Center, TX, USA
    Clin Adv Hematol Oncol 2:572-3. 2004
  90. ncbi Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma
    Janice M Nigro
    Department of Neurological Surgery (Brain Tumor Research Center, University of California, School of Medicine, San Francisco, California, USA
    Cancer Res 65:1678-86. 2005
    ....
  91. ncbi PAX6 suppresses growth of human glioblastoma cells
    Yi Hong Zhou
    Department of Neurobiology and Developmental Sciences, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, 4301 West Markham, Slot 753, Little Rock, AR 72205, USA
    J Neurooncol 71:223-9. 2005
    ..Thus it is interesting to determine if repression of PAX6 expression is involved in anti-tumor suppression function in GBM...
  92. ncbi Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial
    Susan M Chang
    Department of Neurological Surgery, Neuro Oncology Service, University of California at San Francisco, San Francisco, California 94143, USA
    Cancer 100:1712-6. 2004
    ..The objective of the current study was to determine the efficacy and toxicity profile of a combination of these agents before radiotherapy in newly diagnosed AG...
  93. ncbi Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study
    Timothy F Cloughesy
    UCLA Neuro Oncology Program, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, CA 90095, USA
    J Clin Oncol 24:3651-6. 2006
    ..Because tipifarnib undergoes extensive hepatic metabolism, MTD is doubled in patients on EIAEDs. The population included 67 patients with glioblastoma multiforme (GBM) and an exploratory group of 22 patients with anaplastic glioma (AG)...
  94. ncbi Prospective evaluation of quality of life and neurocognitive effects in patients with multiple brain metastases receiving whole-brain radiotherapy with or without thalidomide on Radiation Therapy Oncology Group (RTOG) trial 0118
    Benjamin W Corn
    Department of Radiation Oncology, Tel Aviv Medical Center, Tel Aviv, Israel
    Int J Radiat Oncol Biol Phys 71:71-8. 2008
    ..This secondary analysis of 156 patients examined neurocognitive and quality of life (QOL) outcomes...
  95. ncbi Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas
    Kathleen R Lamborn
    Department of Neurological Surgery, University of California San Francisco, 400 Parnassus Avenue, UC Clinics 808, San Francisco, CA 94143 0372, USA
    Neuro Oncol 10:162-70. 2008
    ..Earlier assessments of progression status also predicted survival and may be incorporated in the design of future clinical trials...

Research Grants20

  1. TRIPLE ANTI ANGIOGENIC THERAPY FOR BRIAN TUMORS
    W K Yung; Fiscal Year: 2002
    ..abstract_text> ..
  2. Analysis of a 10Q Tumor Suppressor Gene
    W K Yung; Fiscal Year: 2007
    ..3) to identify and characterize proteins, which interact with PTEN to form a putative signaling complex, particularly proteins that interact with PTEN at phosphorylated tyrosine 315. ..
  3. Triple Anti-Angiogenic Therapy for Brain Tumors
    W K Yung; Fiscal Year: 2007
    ..abstract_text> ..
  4. Deciphering synergistic combinatorial targets in glioma
    W K Yung; Fiscal Year: 2007
    ....
  5. Deciphering synergistic combinatorial targets in glioma
    W K Yung; Fiscal Year: 2009
    ....
  6. 10Q TUMOR SUPPRESSOR GENE
    W K Yung; Fiscal Year: 2002
    ..This combination of functional and molecular approaches will demonstrate the functional activity of the candidate TS gene and initiate investigations into its mechanism(s) of action. ..
  7. Deciphering synergistic combinatorial targets in glioma
    W K Alfred Yung; Fiscal Year: 2010
    ....